RLS-0071 Moderated Elevated Myeloperoxidase Level and Activity in an Asymptomatic Subject in Clinical Trial RLS-0071-101

26 May 2023 : Case report USA

Unknown etiology, Educational Purpose (only if useful for a systematic review or synthesis)

Jessica M. Goss^1BCDF*, Pamela Hair^1ABCDF, Parvathi S. Kumar^1ADEF, Ulrich Thienel^1AG, Kenji Cunnion^1ACDEFG, Alexander Ellis^2AE

DOI: 10.12659/AJCR.939803

Am J Case Rep 2023; 24:e939803

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Table 2. Subject 1504 Autoantibody panel.

Visit	Test (unit)	Result	Normal reference range
Screening	Anti-double stranded DNA (IU/mL)	<1	0–4
	Antinuclear antibodies	Negative
	Cardiolipin IgG antibody (U/mL)	<1.6	0–20
	Cardiolipin IgM antibody (U/mL)	<0.2	0–20
	Ribonucleoprotein antibody (AI)	0.2	0–1
	Sjogren’s SS-A antibody (AI)	<0.2	0–1
	Sjogren’s SS-B antibody (AI)	<0.2	0–1
	Smith antibody (AI)	<0.2	0–1
Day -1	Antidrug antibody	Negative
Day 6	Antidrug antibody	Negative
	Anti-double stranded DNA (IU/mL)	<1	0–4
	Antinuclear antibodies	Negative
	Cardiolipin IgG antibody (U/mL)	<1.6	0–20
	Cardiolipin IgM antibody (U/mL)	<0.2	0–20
	Ribonucleoprotein antibody (AI)	0.2	0–1
	Sjogren’s SS-A antibody (AI)	<0.2	0–1
	Sjogren’s SS-B antibody (AI)	<0.2	0–1
	Smith antibody (AI)	<0.2	0–1
Follow-up	Anti-double stranded DNA (IU/mL)	<1	0–4
	Antidrug antibody	Negative
	Antinuclear antibodies	Negative
	Cardiolipin IgG antibody (U/mL)	<1.6	0–20
	Cardiolipin IgM antibody (U/mL)	<0.2	0–20
	Ribonucleoprotein antibody (AI)	0.2	0–1
	Sjogren’s SS-A antibody (AI)	<0.2	0–1
	Sjogren’s SS-B antibody (AI)	<0.2	0–1
	Smith antibody (AI)	<0.2	0–1
^* Follow-up visit: Up to 27 days after discharge on Day 6 (Day 30±3 days, Day 27 through Day 33).

Back to the Article